Leksell Cooke has been a dedicated member of the Board since 2017. She has extensive global experience in the software sector, with various positions in Google and, most recently, founded her own company focusing on digital transformation.

Elekta’s business line, Neuro Solutions, encompasses the company’s pioneering systems, Leksell Gamma Knife as well as Leksell Stereotactic Frame. The business line employs approximately 300 individuals who serve customers globally.

“I am delighted that Caroline Leksell Cooke will take on an operational role within Elekta. Her leadership will drive our neuro business forward and enhance our global customer relationships,” said Gustaf Salford, CEO and President. “In recent years, Caroline has played an integral part in developing Elekta as a Board member, and she has been instrumental in representing our neuro business across the globe. Following a comprehensive internal and external recruitment process, she emerged as the ideal candidate to lead this crucial segment of our business.”

Caroline Leksell Cooke added: “I look forward to continuing to advance the neuro solutions that Elekta is renowned for. Over the past seven years, within the Board of Directors, as well as my long international career within the software industry, I have gained invaluable insights and experiences that I will carry with me into my new role. We will now drive our proud legacy forward and bring new innovations to clinicians for the benefit of millions of patients across the world. I am also proud to be the third generation of the Leksell family taking Leksell Gamma Knife into the future.”

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.